D345
PSYCHOPHARMACOLOGY
ADHD & CNS STIMULANT
MEDICATIONS TEST
100 Questions with Answers & Detailed Explanations
100 A-D 100
Practice Questions Multiple Choice Explained Answers
High-Yield Coverage
Amphetamine & methylphenidate • Lisdexamfetamine • Atomoxetine • Guanfacine & clonidine • Bupropion • Cardiovascular
monitoring • Growth & appetite • Sleep • Misuse & diversion • Drug interactions • Psychosis & mania • Combination therapy •
Patient teaching
PASSPOINTPRO
Focused practice. Clear explanations. Stronger recall.
,D345 | ADHD & CNS STIMULANT MEDICATIONS
100-Question Practice Test
Choose the best answer for each question. The correct answer and explanation appear immediately after each item for rapid review.
1. Which statement best describes the primary pharmacologic action of amphetamine-based ADHD
stimulants?
A. They increase synaptic norepinephrine and dopamine, in part by promoting release from presynaptic neurons.
B. They selectively block serotonin reuptake without affecting catecholamines.
C. They directly stimulate postsynaptic GABA-A receptors.
D. They irreversibly inhibit acetylcholinesterase.
Answer: A. They increase synaptic norepinephrine and dopamine, in part by promoting release from presynaptic neurons.
Explanation: Amphetamine products enhance catecholaminergic signaling, especially norepinephrine and dopamine. Their actions
include promoting release and reducing reuptake of these neurotransmitters.
2. A patient taking an amphetamine stimulant reports reduced appetite and difficulty falling asleep. How
should these effects be classified?
A. They indicate serotonin syndrome.
B. They are common stimulant adverse effects that should be assessed in relation to dose and timing.
C. They prove the medication is ineffective.
D. They are specific signs of severe hepatic injury.
Answer: B. They are common stimulant adverse effects that should be assessed in relation to dose and timing.
Explanation: Decreased appetite and insomnia are common with prescription stimulants. Clinical review focuses on severity, timing,
nutrition, sleep, and whether the regimen needs adjustment.
3. Which baseline assessment is especially important before initiating an amphetamine stimulant?
A. Routine weekly serum drug concentrations are required for all patients.
B. A baseline absolute neutrophil count is mandatory because agranulocytosis is expected.
C. Blood pressure, pulse, cardiovascular history, and other risk factors should be reviewed.
D. A fasting ammonia level is the principal safety test.
Answer: C. Blood pressure, pulse, cardiovascular history, and other risk factors should be reviewed.
Explanation: Stimulants can increase heart rate and blood pressure, so cardiovascular history and vital signs are important. Ongoing
monitoring is guided by the patient's risks and clinical response.
4. Which combination is generally contraindicated because of the risk of a dangerous hypertensive reaction?
A. An amphetamine stimulant with a morning meal.
B. An amphetamine stimulant with a noncaffeinated beverage.
C. An amphetamine stimulant with behavioral therapy.
D. An amphetamine stimulant used during treatment with an MAOI or within the required washout interval.
Answer: D. An amphetamine stimulant used during treatment with an MAOI or within the required washout interval.
Explanation: MAOIs can markedly amplify catecholamine effects when combined with stimulants. Product labeling requires avoiding
this combination and observing the appropriate washout period.
PassPointPro | D345 Psychopharmacology Page 2 of 27
, D345 | ADHD & CNS STIMULANT MEDICATIONS
5. Which patient-teaching point is most important for a person prescribed an amphetamine stimulant?
A. Take it only as prescribed, store it securely, and never share it with another person.
B. Double the next dose whenever one dose is missed.
C. Crush all extended-release products to make the effect more predictable.
D. Stop and restart it frequently without discussing the plan with the prescriber.
Answer: A. Take it only as prescribed, store it securely, and never share it with another person.
Explanation: Prescription stimulants carry serious risks of misuse, abuse, addiction, overdose, and diversion. Secure storage and not
sharing the medication are core safety instructions.
6. What is a key pharmacologic effect of methylphenidate?
A. It acts as a selective muscarinic antagonist.
B. It increases dopamine and norepinephrine signaling primarily by blocking their reuptake transporters.
C. It is a direct melatonin-receptor agonist.
D. It suppresses catecholamine release from presynaptic neurons.
Answer: B. It increases dopamine and norepinephrine signaling primarily by blocking their reuptake transporters.
Explanation: Methylphenidate primarily inhibits dopamine and norepinephrine reuptake, increasing their synaptic availability. This
catecholaminergic effect contributes to improved attention and impulse control in ADHD.
7. A patient taking methylphenidate develops persistent resting tachycardia. What is the best interpretation?
A. It is expected and should never be monitored.
B. It confirms lithium toxicity.
C. The finding warrants clinical reassessment because stimulants can increase heart rate and blood pressure.
D. It is diagnostic of neuroleptic malignant syndrome.
Answer: C. The finding warrants clinical reassessment because stimulants can increase heart rate and blood pressure.
Explanation: Stimulants can raise pulse and blood pressure. Persistent or clinically significant cardiovascular changes should be
evaluated rather than automatically dismissed as harmless.
8. Which instruction is appropriate for many long-acting methylphenidate formulations?
A. All long-acting products must be crushed before administration.
B. Every long-acting formulation can be substituted milligram-for-milligram without review.
C. The formulation never affects onset or duration.
D. Follow the specific product instructions because extended-release formulations are not interchangeable in how they are taken.
Answer: D. Follow the specific product instructions because extended-release formulations are not interchangeable in
how they are taken.
Explanation: Methylphenidate products use different release technologies and administration instructions. Prescribers and patients
should follow the specific labeling rather than assume all extended-release products behave identically.
PassPointPro | D345 Psychopharmacology Page 3 of 27
PSYCHOPHARMACOLOGY
ADHD & CNS STIMULANT
MEDICATIONS TEST
100 Questions with Answers & Detailed Explanations
100 A-D 100
Practice Questions Multiple Choice Explained Answers
High-Yield Coverage
Amphetamine & methylphenidate • Lisdexamfetamine • Atomoxetine • Guanfacine & clonidine • Bupropion • Cardiovascular
monitoring • Growth & appetite • Sleep • Misuse & diversion • Drug interactions • Psychosis & mania • Combination therapy •
Patient teaching
PASSPOINTPRO
Focused practice. Clear explanations. Stronger recall.
,D345 | ADHD & CNS STIMULANT MEDICATIONS
100-Question Practice Test
Choose the best answer for each question. The correct answer and explanation appear immediately after each item for rapid review.
1. Which statement best describes the primary pharmacologic action of amphetamine-based ADHD
stimulants?
A. They increase synaptic norepinephrine and dopamine, in part by promoting release from presynaptic neurons.
B. They selectively block serotonin reuptake without affecting catecholamines.
C. They directly stimulate postsynaptic GABA-A receptors.
D. They irreversibly inhibit acetylcholinesterase.
Answer: A. They increase synaptic norepinephrine and dopamine, in part by promoting release from presynaptic neurons.
Explanation: Amphetamine products enhance catecholaminergic signaling, especially norepinephrine and dopamine. Their actions
include promoting release and reducing reuptake of these neurotransmitters.
2. A patient taking an amphetamine stimulant reports reduced appetite and difficulty falling asleep. How
should these effects be classified?
A. They indicate serotonin syndrome.
B. They are common stimulant adverse effects that should be assessed in relation to dose and timing.
C. They prove the medication is ineffective.
D. They are specific signs of severe hepatic injury.
Answer: B. They are common stimulant adverse effects that should be assessed in relation to dose and timing.
Explanation: Decreased appetite and insomnia are common with prescription stimulants. Clinical review focuses on severity, timing,
nutrition, sleep, and whether the regimen needs adjustment.
3. Which baseline assessment is especially important before initiating an amphetamine stimulant?
A. Routine weekly serum drug concentrations are required for all patients.
B. A baseline absolute neutrophil count is mandatory because agranulocytosis is expected.
C. Blood pressure, pulse, cardiovascular history, and other risk factors should be reviewed.
D. A fasting ammonia level is the principal safety test.
Answer: C. Blood pressure, pulse, cardiovascular history, and other risk factors should be reviewed.
Explanation: Stimulants can increase heart rate and blood pressure, so cardiovascular history and vital signs are important. Ongoing
monitoring is guided by the patient's risks and clinical response.
4. Which combination is generally contraindicated because of the risk of a dangerous hypertensive reaction?
A. An amphetamine stimulant with a morning meal.
B. An amphetamine stimulant with a noncaffeinated beverage.
C. An amphetamine stimulant with behavioral therapy.
D. An amphetamine stimulant used during treatment with an MAOI or within the required washout interval.
Answer: D. An amphetamine stimulant used during treatment with an MAOI or within the required washout interval.
Explanation: MAOIs can markedly amplify catecholamine effects when combined with stimulants. Product labeling requires avoiding
this combination and observing the appropriate washout period.
PassPointPro | D345 Psychopharmacology Page 2 of 27
, D345 | ADHD & CNS STIMULANT MEDICATIONS
5. Which patient-teaching point is most important for a person prescribed an amphetamine stimulant?
A. Take it only as prescribed, store it securely, and never share it with another person.
B. Double the next dose whenever one dose is missed.
C. Crush all extended-release products to make the effect more predictable.
D. Stop and restart it frequently without discussing the plan with the prescriber.
Answer: A. Take it only as prescribed, store it securely, and never share it with another person.
Explanation: Prescription stimulants carry serious risks of misuse, abuse, addiction, overdose, and diversion. Secure storage and not
sharing the medication are core safety instructions.
6. What is a key pharmacologic effect of methylphenidate?
A. It acts as a selective muscarinic antagonist.
B. It increases dopamine and norepinephrine signaling primarily by blocking their reuptake transporters.
C. It is a direct melatonin-receptor agonist.
D. It suppresses catecholamine release from presynaptic neurons.
Answer: B. It increases dopamine and norepinephrine signaling primarily by blocking their reuptake transporters.
Explanation: Methylphenidate primarily inhibits dopamine and norepinephrine reuptake, increasing their synaptic availability. This
catecholaminergic effect contributes to improved attention and impulse control in ADHD.
7. A patient taking methylphenidate develops persistent resting tachycardia. What is the best interpretation?
A. It is expected and should never be monitored.
B. It confirms lithium toxicity.
C. The finding warrants clinical reassessment because stimulants can increase heart rate and blood pressure.
D. It is diagnostic of neuroleptic malignant syndrome.
Answer: C. The finding warrants clinical reassessment because stimulants can increase heart rate and blood pressure.
Explanation: Stimulants can raise pulse and blood pressure. Persistent or clinically significant cardiovascular changes should be
evaluated rather than automatically dismissed as harmless.
8. Which instruction is appropriate for many long-acting methylphenidate formulations?
A. All long-acting products must be crushed before administration.
B. Every long-acting formulation can be substituted milligram-for-milligram without review.
C. The formulation never affects onset or duration.
D. Follow the specific product instructions because extended-release formulations are not interchangeable in how they are taken.
Answer: D. Follow the specific product instructions because extended-release formulations are not interchangeable in
how they are taken.
Explanation: Methylphenidate products use different release technologies and administration instructions. Prescribers and patients
should follow the specific labeling rather than assume all extended-release products behave identically.
PassPointPro | D345 Psychopharmacology Page 3 of 27
